BRAF and neoplasm: Second, because the treatment regimen was decided by the physician's choice, some significant background differences were observed, mainly for the primary tumor location, BRAF status, MSI status, and combined cytotoxic agents (doublet/mono or triplet), which reflect the present standard‐of‐care in the world.